EuroBiotech—More Articles of Note


> Oculis extended its series B by CHF 15.5 million ($15.8 million), bringing the total size of the round up to CHF 35.5 million. The Swiss ophthalmic drug specialist unveiled the extension alongside news that it has licensed an anti-TNF alpha antibody from Novartis. Statement | More

> Germany’s Immunic is set to land on Nasdaq through a merger with Vital Therapies. The combined company will take Immunic’s name and advance its existing pipeline of chronic inflammatory and autoimmune disease drugs using a €26 million ($30 million) commitment from an investor syndicate. Release 

> Celgene helped AI drug discovery shop Exscientia to a $26 million series B round. Exscientia shared the news alongside details of a deal with Roche that is worth up to CHF 67 million. Statement | More


How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

> Nanobiotix teamed up with the MD Anderson Cancer Center to develop anticancer drug NBTXR3. MD Anderson will initiate nine phase 1/2 trials of the drug in return for up to $12 million. Release 

> Hvivo claimed success in a phase 2b flu trial after using a different assay to assess samples for the primary endpoint. The initial analysis found that the trial missed its primary endpoint, only for the other, more sensitive assay to reveal the opposite. Statement 

> Galapagos secured the global rights to a treatment for idiopathic pulmonary fibrosis that is in development at Fibrocor Therapeutics. Release 

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.